Achilles Therapeutics Azioni (NASDAQ: ACHL)

Ultime notizie per Achilles Therapeutics (NASDAQ:ACHL) Azioni

Achilles Therapeutics

Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.

Achilles Therapeutics plc - American Depositary Shares

Achilles Therapeutics PLC

Outset Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OM#NASDAQ">OM</a>) raises FY2024 sales outlook from $110.00 million to $112.00 million.

News

Guidance

Outset Medical Raises FY2024 Sales Guidance from $110.00M to $112.00M

Shares of Robinhood Markets Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) surged close to 20% on Wednesday following Donald Trump's victory in the U.S. presidential election. Here&#8217;s <a href="https://www.benzinga.com//node/41784504">what you need to know.</a>
What To Know: Investors are expecting less regulation, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41792455/jpmorgan-bank-of-america-and-wells-fargo-shares-surged-wednesday-heres-why">reduced oversight</a> from agencies like the Consumer Financial Protection Bureau (CFPB) with Trump set to return to the White House, per <a href="https://www.cnbc.com/2024/11/05/stock-market-today-live-updates.html">CNBC</a>.
"Trump is viewed as supporting lower corporate tax rates, deregulation, and industrial policies that favor domestic growth, all of which could provide more stimulus to the U.S. economy and benefit risk assets,&#8221; Marc Pinto, head of Americas equities at Janus Henderson, said in a new note.
The dollar index rose to its highest level since July, as investors believe Trump's proposed tariffs could strengthen the U.S. dollar. Meanwhile, the 10-year Treasury yield climbed to about 4.43%, driven by anticipation that Trump's potential tax cuts and spending plans could boost economic growth, but increase the fiscal deficit and lead to higher inflation.
Robinhood shares may have also gotten a boost on Wednesday thanks to strong overnight trading activity and election contracts data.
The company reported its <a href="https://www.benzinga.com/fintech/24/11/41783293/robinhood-reports-record-overnight-trading-volume-400-million-2024-election-contracts-traded">largest overnight session</a> since launching its 24-hour market, with trading volumes around 11 times higher than the company&#8217;s average overnight volume. 
Check This Out: <a href="https://www.benzinga.com/fintech/24/11/41783293/robinhood-reports-record-overnight-trading-volume-400-million-2024-election-contracts-traded">Robinhood Reports Record Overnight Trading Volume, 400 Million 2024 Election Contracts Traded</a>
Overnight trading volumes included election contracts, which hit a milestone of 400 million contracts traded. More than 500,000 Robinhood users took part in election contract trading, according to the company.
Robinhood stock also traded higher alongside several crypto-related stocks on Wednesday. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) climbed to new all-time highs above $75,000, which sent crypto-linked stocks racing higher. Trump had positioned himself as a pro-crypto candidate.
Hood Price Action: Robinhood shares closed Wednesday up 19.6% at $29.86, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/41785036/elon-musk-and-joe-rogan-criticize-psychedelics-and-big-pharmas-legacy-of-profit-over-public-heal">Elon Musk And Joe Rogan Criticize Psychedelics And Big Pharma&#8217;s Legacy Of Profit Over Public Health</a></li>
</ul>
Image via Shutterstock.

Movers

$BTC

HOOD

Robinhood Markets Stock Jumped 20% On Wednesday: What Happened?

OTC Markets Gr (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OTCM#OTC">OTCM</a>) reported quarterly earnings of $0.89 per share which beat the analyst consensus estimate of $0.60 by 48.33 percent. The company reported quarterly sales of $26.634 million which missed the analyst consensus estimate of $27.074 million by 1.63 percent. This is a 1.53 percent increase over sales of $26.232 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

OTCM

OTC Markets Gr Q3 2024 Adj. EPS $0.89 Beats $0.60 Estimate, Sales $26.634M Miss $27.074M Estimate

LegalZoom.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LZ#NASDAQ">LZ</a>) narrows FY2024 sales outlook from $675.00 million-685.00 million to $678.00 million-682.00 million.

LegalZoom.com Narrows FY2024 Sales Guidance from $675.00M-685.00M to $678.00M-682.00M

LegalZoom.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LZ#NASDAQ">LZ</a>) sees Q4 sales of $158.000 million-162.000 million vs $161.47 million estimate.

LegalZoom.com Sees Q4 Sales $158.000M-162.000M vs $161.47M Est

LegalZoom.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LZ#NASDAQ">LZ</a>) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.15 by 13.33 percent. The company reported quarterly sales of $168.599 million which beat the analyst consensus estimate of $167.472 million by 0.67 percent. This is a 0.79 percent increase over sales of $167.274 million the same period last year.

LegalZoom.com Q3 2024 Adj. EPS $0.17 Beats $0.15 Estimate, Sales $168.599M Beat $167.472M Estimate

Laird Superfood (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LSF#AMEX">LSF</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.07) by 128.57 percent. The company reported quarterly sales of $11.776 million which beat the analyst consensus estimate of $10.479 million by 12.38 percent. This is a 28.28 percent increase over sales of $9.180 million the same period last year.

Laird Superfood Q3 2024 Adj. EPS $0.02 Beats $(0.07) Estimate, Sales $11.776M Beat $10.479M Estimate

Sports betting and online gaming company DraftKings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) could highlight early results from the 2024 NFL season and new state legalizations when the company reports third-quarter financial results Thursday<a href="https://www.benzinga.com/earnings"> after market close.</a>
Earnings Estimates: Analysts expect the company to report third-quarter revenue of $1.11 billion, up from last year's third-quarter total of $789.96 million according to data <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1">from Benzinga Pro.</a>
The company missed analyst estimates for revenue for the second quarter and two of the past three quarters, but has beaten analyst estimates for revenue in eight of the last 10 quarters overall.
Analysts expect DraftKings to report a loss of 42 cents per share in the third quarter, compared to a loss of 35 cents per share in last year's third quarter. The company has beaten analyst estimates for earnings per share in 10 straight quarters.
Read Also: <a href="https://www.benzinga.com/general/politics/24/11/41725070/draftkings-offers-10k-in-prizes-for-2024-election-predictions-harris-trump-swing-state-performan">DraftKings Offers $10K In Prizes For 2024 Election Predictions: Harris, Trump Swing State Performance Among Key Questions</a>
What Analysts Are Saying: Strong market share in the sports betting space and the potential to surprise with updated financial guidance has Bank of America analyst Shaun C. Kelley bullish on DraftKings <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41589183/draftkings-stock-to-hit-new-52-week-highs-bullish-analyst-on-2025-guidance-upside-o">ahead of the earnings report.</a>
The analyst, who has a Buy rating and $50 price target, recently said revenue flowthrough for the second half of the fiscal year could be better than expected and "protect" EBITDA for fiscal 2024.
"We expect top-line growth in the fourth quarter to come in slightly below guidance driven by unfavorable hold and challenging iGaming comps," Kelley said.
The analyst said DraftKings could also show its hold expansion similar to peer FanDuel with lower promotional spending activity.
Concerns for DraftKings in the third quarter include slower app downloads and unfavorable NFL game outcomes, Kelley added.
A near duopoly of the online sports betting space for DraftKings and FanDuel owner Flutter Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>) <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40985921/flutter-analyst-sees-significant-earnings-power-with-growing-duopoly-sports-betting">was highlighted by </a>Needham analyst Bernie McTernan recently.
McTernan said the total addressable market size of the U.S. online sports betting market could "continue to surprise to the upside."
&#8220;Scale and commitment to product leadership from FanDuel and DKNG likely keeps the OSB market dominated by these two players," McTernan said.
A Needham survey revealed that sports bettors primarily use FanDuel and DraftKings.
&#8220;We think share can continue to ebb and flow between FanDuel and DKNG as we do not see a physical network effect in OSB meaning there is not a structural reason for dominant market share leader like digital marketplaces.&#8221;
McTernan said unless the market structure in the U.S. changes, it&#8217;s &#8220;FanDuel and DKNG at the top and then everyone else.&#8221;
FanDuel (37.8%) and DraftKings (34.8%) had a combined 73% market share in 2023. BetMGM ranks a distant third at 8.6% market share.
In the second quarter of 2024, FanDuel had a market share of 37.3% with DraftKings at 37.0%. Both BetMGM and fourth-place Caesars had lower market share in the first two quarters of 2024 compared to 2023.
Key Items to Watch: DraftKings quarterly financial results come after the start of the 2024 NFL season, which is one of the most bet on sports in the U.S. and a key to revenue and earnings for the company in the fourth quarter.
Guidance from the company and early commentary on the NFL season will be closely watched by investors.
The company<a href="https://www.benzinga.com/news/earnings/24/08/40116073/draftkings-q2-earnings-highlights-sports-betting-company-launches-1-billion-buyback-misses-on-reven"> announced an inaugural</a> $1 billion share buyback in the second quarter. Investors and analysts will be watching to see if any shares were bought during the third quarter.
DraftKings acquisition of Jackpocket led to lower average revenue per monthly unique paying customer in the second quarter and could be an area to watch for investors and analysts.
As of July 25, DraftKings is live with mobile sports betting in 25 states and Washington, D.C., representing 49% of the U.S. population.
The company is live with iGaming in five states.
On Tuesday, voters in Missouri approved sports betting, becoming the 39th state to legalize. There is no current timetable on when the state will be live, but DraftKings and FanDuel supported the ballot proposal.
Missouri is the 18th most populous state and fourth-largest state that has not yet legalized sports betting, according to a report from <a href="https://www.sportico.com/business/sports-betting/2024/missouri-sports-betting-ballot-measure-caesars-draftkings-fanduel-1234803926/">Sportico</a>.
DraftKings previously said there were 10 jurisdictions representing 12% of the U.S. population that have introduced legislation or introduced a bill for a referendum to legalize mobile sports betting.
An update on the timetable in Missouri and where other states stand could come from the company on Thursday.
DKNG Price Action: DraftKings stock was up 4.94% to $38.25 on Wednesday at market close versus a 52-week trading range of $28.69 to $49.57. DraftKings stock is up 14% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41402089/goldman-sachs-highlights-20-top-short-squeeze-opportunities-for-q3-earnings-season">Goldman Sachs Highlights 20 Top Short-Squeeze Opportunities For Q3 Earnings Season</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Sports Betting

Previews

Analyst Ratings

Trading Ideas

DKNG

FLUT

DraftKings Q3 Earnings Highlights: NFL In Focus, Will Missouri Legalization Factor Into Guidance?

CDMO

Trading Halt: Halt status updated at 6:30:00 PM ET: Quotation Resumption: News and Resumption Times

Redwire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.14) by 164.29 percent. This is a 164.29 percent decrease over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $68.638 million which missed the analyst consensus estimate of $70.514 million by 2.66 percent. This is a 9.62 percent increase over sales of $62.612 million the same period last year.

Redwire Q3 2024 GAAP EPS $(0.37) Misses $(0.14) Estimate, Sales $68.638M Miss $70.514M Estimate

Viemed Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMD#NASDAQ">VMD</a>) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.07 by 42.86 percent. This is a 42.86 percent increase over earnings of $0.07 per share from the same period last year. The company reported quarterly sales of $58.004 million which beat the analyst consensus estimate of $57.150 million by 1.49 percent. This is a 17.41 percent increase over sales of $49.402 million the same period last year.

Viemed Healthcare Q3 2024 GAAP EPS $0.10 Beats $0.07 Estimate, Sales $58.004M Beat $57.150M Estimate

Genworth Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNW#NYSE">GNW</a>) reported quarterly earnings of $0.11 per share which missed the analyst consensus estimate of $0.19 by 42.11 percent. This is a 22.22 percent increase over earnings of $0.09 per share from the same period last year. The company reported $1.88 billion in sales this quarter. This is a 2.68 percent increase over sales of $1.83 billion the same period last year.

Genworth Finl Q3 Adj $0.11 Misses $0.19 Estimate, Sales $1.88B Up From $1.83B YoY

Park-Ohio Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PKOH#NASDAQ">PKOH</a>) reported quarterly earnings of $1.07 per share which beat the analyst consensus estimate of $0.89 by 20.22 percent. The company reported quarterly sales of $417.600 million which missed the analyst consensus estimate of $438.700 million by 4.81 percent. This is a 0.29 percent decrease over sales of $418.800 million the same period last year.

PKOH

Park-Ohio Hldgs Q3 2024 Adj. EPS $1.07 Beats $0.89 Estimate, Sales $417.600M Miss $438.700M Estimate

Liberty Latin America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILA#NASDAQ">LILA</a>) reported quarterly losses of $(2.22) per share which missed the analyst consensus estimate of $0.05 by 4540 percent. The company reported quarterly sales of $1.089 billion which missed the analyst consensus estimate of $1.128 billion by 3.44 percent. This is a 3.29 percent decrease over sales of $1.126 billion the same period last year.

LILA

Liberty Latin America Q3 2024 GAAP EPS $(2.22) Misses $0.05 Estimate, Sales $1.089B Miss $1.128B Estimate

Gold production in 2025 is expected to increase significantly relative to 2024 as a result of the scheduled mining and processing of higher-grade ore from the Fekola and Cardinal pits made accessible by the meaningful stripping campaign that has been undertaken throughout 2024, the expected full year of contribution from Fekola Regional, which is anticipated to contribute between 80,000 and 100,000 ounces of additional production, and commencement of mining the higher-grade Fekola underground (subject to receipt of necessary permits for Fekola Regional and Fekola underground).

B2Gold Expects Total Gold Production For 2024 To Be Towards Low End Of Guidance Range Of 800,000 - 870,000 Ounces; Expects Gold Production In 2025 To Increase Significantly Relative To 2024

OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) raises FY2024 sales outlook from $200.00 million-203.00 million to $202.00 million-204.00 million.

KIDS

OrthoPediatrics Raises FY2024 Sales Guidance from $200.00M-203.00M to $202.00M-204.00M

Montrose Environmental Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEG#NYSE">MEG</a>) reported quarterly earnings of $0.41 per share which beat the analyst consensus estimate of $0.35 by 17.14 percent. This is a 32.26 percent increase over earnings of $0.31 per share from the same period last year. The company reported quarterly sales of $178.69 million which missed the analyst consensus estimate of $185.47 million by 3.66 percent. This is a 6.40 percent increase over sales of $167.94 million the same period last year.

Montrose Environmental Gr Q3 Adj $0.41 Beats $0.35 Estimate, Sales $178.69M Miss $185.47M Estimate

B2Gold (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BTG#AMEX">BTG</a>) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.05 by 60 percent. This is a 60 percent decrease over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $448.23 million which beat the analyst consensus estimate of $444.81 million by 0.77 percent. This is a 6.21 percent decrease over sales of $477.89 million the same period last year.

B2Gold Q3 2024 Adj EPS $0.02 Misses $0.05 Estimate, Sales $448.23M Beat $444.81M Estimate

Lower than expected gold production at Candelaria and slower ramp-ups at newly contributing mines have resulted in fewer Precious Metal GEOs than originally anticipated. In addition, record gold prices in the current year have impacted the conversion of non-gold revenue into GEOs.&nbsp;

Franco-Nevada Expects Full-year 2024 Revenue To Be $1.05B - $1.15B, Est $1.127B

Trinseo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSE#NYSE">TSE</a>) reported quarterly losses of $(1.62) per share which missed the analyst consensus estimate of $(1.47) by 10.2 percent. This is a 57.28 percent decrease over losses of $(1.03) per share from the same period last year. The company reported quarterly sales of $867.700 million which missed the analyst consensus estimate of $887.550 million by 2.24 percent. This is a 1.29 percent decrease over sales of $879.000 million the same period last year.

Trinseo Q3 2024 Adj. EPS $(1.62) Misses $(1.47) Estimate, Sales $867.700M Miss $887.550M Estimate

Achilles Therapeutics Plc (ACHL) has released an update. Achilles Therapeutics Plc, a biopharmaceutical company, has received a notice from Nasdaq ...

Achilles Therapeutics Addresses Nasdaq Notice

Achilles Therapeutics receives Nasdaq notice for non-compliance

Achilles Therapeutics (ACHL) has released an update. Achilles Therapeutics has announced its Annual General Meeting (AGM) for shareholders to be he...

Achilles Therapeutics Calls for AGM Participation

Achilles Therapeutics (ACHL) has released an update. Achilles Therapeutics plc successfully held its Annual General Meeting in June 2024, with all ...

Achilles Therapeutics AGM Concludes with Key Approvals

Achilles Therapeutics (ACHL) has released an update. Achilles Therapeutics has announced changes in its leadership, with Karl Peggs stepping down a...

Leadership Shift at Achilles Therapeutics

Achilles Therapeutics (ACHL) has released an update. Achilles Therapeutics has reported a promising second quarter with a strategic collaboration w...

Achilles Therapeutics Excels in Q2 with Promising Trials

Achilles Therapeutics GAAP EPS of -$0.41

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Achilles Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/achl-stock-quote/">ACHL</a>) just reported results for the second quarter of 2024.<ul><li>Achilles Therapeutics reported earnings per share of -41 cents. This met the analyst estimate for EPS of -41 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/achl-stock-earnings-achilles-therapeutics-for-q2-of-2024/">ACHL Stock Earnings: Achilles Therapeutics Meets EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ACHL Stock Earnings: Achilles Therapeutics Meets EPS for Q2 2024

Achilles Therapeutics (ACHL) has released an update. Achilles Therapeutics has halted its TIL-based cNeT therapy development and is closing its CHI...

Achilles Therapeutics Shifts Strategy, Seeks Alternatives

Achilles climbs after decision to find strategic alternatives

ACHL

Press Releases

Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

Health Care

Achilles Therapeutics Announces Publication of Nature Cancer 'Comment' on Strategy for Improved Neoantigen Immunogenicity Prediction

Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference

Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning

Comments

Achilles Therapeutics

Notizie

Ultime notizie per Achilles Therapeutics (NASDAQ:ACHL) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO